Pharmaceutical

J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius

The deal sets the biosimilar’s potential US launch date to no later than April 2025, following two agreements signed earlier this year.

Aug 8, 2023 - 20:00
J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius
The deal sets the biosimilar’s potential US launch date to no later than April 2025, following two agreements signed earlier this year.
Read the original article

Tags:

Previous Article

Astellas invests $50m in Poseida’s CAR-T cell therapy

Next Article

Arcus and Gilead terminate development for etrumadenant in prostate cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Clinigen clears out cancer therapies in line with latest growth strategy

Clinigen clears out cancer therapies in line with lates...

Aug 12, 2023

Opinion: A seemingly small semantic issue is a major roadblock to develop treatments for rare diseases

Opinion: A seemingly small semantic issue is a major ro...

Jun 28, 2023

STAT+: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain

STAT+: Moonlake’s less-than-transparent data disclosure...

Jun 28, 2023